@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc as detected by an fda approved test alecensa is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase alk positive metastatic non small cell lung cancer nsclc as detected by an fda approved test 1";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "SDY4nf+rJbnG7663eQB0naOJiOYdfId9JAbIX8K6TJpz85nPPPVfqoHk7Lg4QztN1dvELwEOgCNjWGVGVMVn3GMfAjMEYzRNvmkTV23/XCS/wTTranHAwPpkiFdKzl1hsL5iCqc2lGzsYofx+BT/GC2ocHTWXT8KJnaE2X0UfWI=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-07-03T14:52:14.244+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}